Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
Metsera (MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced its participation in TD Cowen's 45th Annual Health Care Conference.
The company's CEO, Whit Bernard, is scheduled to deliver a presentation on Tuesday, March 4, 2025, from 1:10 to 1:40 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & News section at investors.metsera.com. The presentation recording will remain accessible for 90 days after the event.
Metsera (MTSR), un'azienda biofarmaceutica in fase clinica focalizzata sull'obesità e sulle malattie metaboliche, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
Il CEO dell'azienda, Whit Bernard, è programmato per presentare il martedì 4 marzo 2025, dalle 13:10 alle 13:40 ET. Gli investitori e le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la pagina Eventi nella sezione Investitori & Notizie su investors.metsera.com. La registrazione della presentazione rimarrà accessibile per 90 giorni dopo l'evento.
Metsera (MTSR), una empresa biofarmacéutica en etapa clínica centrada en la obesidad y las enfermedades metabólicas, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen.
El CEO de la empresa, Whit Bernard, está programado para ofrecer una presentación el martes 4 de marzo de 2025, de 1:10 a 1:40 p.m. ET. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la página de Eventos en la sección de Inversores y Noticias en investors.metsera.com. La grabación de la presentación estará disponible durante 90 días después del evento.
Metsera (MTSR), 비만 및 대사 질환에 중점을 둔 임상 단계의 생명공학 회사가 TD Cowen의 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다.
회사의 CEO인 Whit Bernard는 2025년 3월 4일 화요일 오후 1시 10분부터 1시 40분(ET)까지 발표를 할 예정입니다. 투자자 및 관심 있는 분들은 investors.metsera.com의 투자자 및 뉴스 섹션의 이벤트 페이지를 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이벤트 후 90일 동안 접근 가능합니다.
Metsera (MTSR), une entreprise biopharmaceutique en phase clinique axée sur l'obésité et les maladies métaboliques, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen.
Le PDG de l'entreprise, Whit Bernard, doit présenter le mardi 4 mars 2025, de 13h10 à 13h40 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la page Événements dans la section Investisseurs & Actualités sur investors.metsera.com. L'enregistrement de la présentation restera accessible pendant 90 jours après l'événement.
Metsera (MTSR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Fettleibigkeit und Stoffwechselerkrankungen konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
Der CEO des Unternehmens, Whit Bernard, wird am Dienstag, den 4. März 2025, von 13:10 bis 13:40 Uhr ET eine Präsentation halten. Investoren und Interessierte können über die Veranstaltungsseite im Bereich Investoren & Nachrichten auf investors.metsera.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for 90 days following the event.
About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.
Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the “Email Alerts” option on the Investors & Media page and submitting your email address.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the Company’s planned participation in and content of the Company’s presentation at TD Cowen’s 45th Annual Health Care Conference, including the date and time of such event. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption “Risk Factors” in its filings with the Securities and Exchange Commission, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at investors.metsera.com. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company’s views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact:
Vicki Albrecht
Metsera
media@metsera.com
FAQ
When is Metsera (MTSR) presenting at TD Cowen's Health Care Conference 2025?
How can investors watch Metsera's (MTSR) presentation at the TD Cowen conference?
How long will Metsera's (MTSR) TD Cowen conference presentation be available for replay?
What is Metsera's (MTSR) primary focus as a biopharmaceutical company?
